Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022
Number of shares and voting rights of Innate Pharma as of December 1, 2022
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Innate Pharma Reports Third Quarter Financial Results
Innate Pharma announces conference call and webcast for third quarter 2022 business update
Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022
Innate Pharma to participate in upcoming investor conferences
Innate Pharma 2023 financial calendar
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced mycosis fungoides
